logo
James Van Der Beek on Colorectal Cancer: 'It's Harder Than I Thought It Would Be'

James Van Der Beek on Colorectal Cancer: 'It's Harder Than I Thought It Would Be'

Health Line4 hours ago
James Van Der Beek shares his journey with early onset colorectal cancer after being diagnosed at 46.
The former 'Dawson's Creek' star is spreading awareness about the rising cases of colorectal cancer in young people.
Van Der Beek teamed up with Guardant Health to inform others about the importance of colon cancer screening and early detection.
At 46 years old, actor James Van Der Beek noticed minor changes in his bowel movements.
'There wasn't any red flag or something glaring,' he told Healthline.
However, out of caution, the 'Dawson's Creek' star felt the need to see his doctor. After undergoing a colonoscopy in August 2023, Van Der Beek learned he had colorectal cancer.
'I was healthy. I was doing the cold plunge. I was in amazing cardiovascular shape, and I had stage 3 cancer, and I had no idea,' he said.
Because his cancer occurred before age 50, it is considered early onset colorectal cancer. Rates of early onset colorectal cancer in the United States have nearly doubled since the early 1990s. In 1994, the incidence rate was 4.8 cases per 100,000 people, and in 2021, it rose to 10.1 per 100,000 people.
'With this upward trend of 2–4% annually, gastroenterologists and colorectal surgeons are very concerned that we may not be capturing the full scope of the disease early enough, particularly in asymptomatic younger individuals who do not meet traditional risk-based criteria,' Paul Johnson, MD, surgical oncologist with Methodist Le Bonheur Healthcare, told Healthline.
In 2018, due to the alarming rise in the incidence of young-onset colorectal cancer, the American Cancer Society lowered the screening age for average-risk patients from 50 to 45. In 2021, the U.S. Preventive Services Task Force (USPSTF) echoed this recommendation, stating that colon cancer screening should begin for all adults ages 45–49.
A research letter published on August 4 in JAMA Network notes that the 50% increase in colorectal cancer incidence from 2021 to 2022 is likely a reflection of the recent changes to colon cancer screening guidelines for adults under 50.
Getting screened for colon cancer can lead to early detection, which improves survival and decreases the likelihood of needing chemotherapy, immunotherapy, or radiation, Johnson noted. When colorectal cancer is caught in early stages, survival is over 90%. A doctor can help determine if a stool-based test that looks for cancer is the best option or if a colonoscopy, which examines the colon and rectum, is best.
'The proverb 'an ounce of prevention is worth a pound of cure' is very apropos because we know that if we remove polyps, an abnormal growth in the lining of the colon or rectum, we can interrupt the pathway of that polyp becoming cancer,' Johnson said.
While colonoscopy remains the gold standard of screening and can detect polyps with remarkable accuracy, he said, the procedure also allows doctors to remove the polyps on the spot, thereby preventing development into cancer.
However, he noted that newer options, such as stool DNA-based colorectal cancer screening tests and the FDA-approved blood-based test Shield, have introduced additional options.
To encourage people to get screened, Van Der Beek partnered with Guardant Health to raise awareness about the Shield blood test. 'I really want to impress upon people that you don't need symptoms to get screened. If you are 45 or older or have a family history, talk to your doctor about your screening options,' he said.
Healthline talked with Van Der Beek to hear more about his cancer journey and why he is speaking out.
This interview has been lightly edited and condensed for clarity and length.
What should people to know about colon cancer?
Van Der Beek: I want to unpack the numbers. It is the second leading cause of cancer death, but if you look closer, it's also the most curable.
I really want people to understand that [when found] in the early stages, the survival rates skyrocket.
Before my diagnosis, I didn't know much about colorectal cancer. I didn't even realize the screening age dropped to 45; I thought it was still 50.
Just put [screening] on your radar, even if you're young, even if you're healthy because unfortunately cases are rising, especially in younger, healthier people.
Did your diagnosis give you a new perspective on life?
Van Der Beek: Oh, for sure. I think I take things a little bit more slowly. I think I've learned to really appreciate the small moments and to let go of the things that would've upset me prior.
It's really taught me a lot about myself, how important self-love is, and how important positive self-talk is. It's really made me take a good, hard look at who I am.
How did your cancer diagnosis affect your mental health?
Van Der Beek: It is challenging. In the beginning, one thing I used to say a lot was, 'This is harder than I thought it would be.'
I would say find out who you can lean on and ask for help. Really find who your people are and reach out. You can't do this alone.
That was the biggest [challenge] for me because I never asked for help. And what I realized was just how many people were there to show up for me, how I'd been wronging them of the opportunity to show up because I try to do everything all the time.
How important is preventive healthcare?
Van Der Beek: Colorectal cancer just wasn't on my radar before, so yeah, I've got a much greater awareness and I'm the one telling all my friends to talk to their doctor, find out about screening options.
What I love about the Shield test is it's convenient, simple, FDA approved — it's a simple blood draw and it could be done at your next doctor's appointment.
Obviously, colonoscopy is still the gold standard for screening, but for anybody who has barriers around that, what they found is that adherence to a colonoscopy recommendation is not that great.
But people are three times more likely to adhere to [screening] advice when it's just a blood test. It's convenient for people who either can't take off work to do a colonoscopy or who [face] other barriers to some of the other testing methods.
How does it feel to share your cancer journey?
Van Der Beek: It is really life affirming. I feel like it's a big part of my healing process to spread the word and to help anybody I can from having to go through what I have been through.
Using a platform for a purpose is definitely a lot more fun than trying to push my next project, which I'm not above doing. [I] get to spread the word and feel like everything I've been going through has purpose.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Diversified Healthcare Trust Announces Second Quarter 2025 Results
Diversified Healthcare Trust Announces Second Quarter 2025 Results

Yahoo

time27 minutes ago

  • Yahoo

Diversified Healthcare Trust Announces Second Quarter 2025 Results

NEWTON, Mass., August 04, 2025--(BUSINESS WIRE)--Diversified Healthcare Trust (Nasdaq: DHC) today announced its financial results for the quarter ended June 30, 2025, which can be found at the Quarterly Reports section of DHC's website at A conference call to discuss DHC's second quarter 2025 financial results will be held on Tuesday, August 5, 2025 at 10:00 a.m. Eastern Time. The conference call may be accessed by dialing (877) 329-4297 or (412) 317-5435 (if calling from outside the United States and Canada); a pass code is not required. A replay will be available for one week by dialing (877) 344-7529; the replay pass code is 1592130. A live audio webcast of the conference call will also be available in a listen-only mode on DHC's website, at The archived webcast will be available for replay on DHC's website after the call. The transcription, recording and retransmission in any way of DHC's second quarter conference call are strictly prohibited without the prior written consent of DHC. About Diversified Healthcare Trust: DHC is a real estate investment trust focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum by care delivery and practice type, by scientific research disciplines and by property type and location. As of June 30, 2025, DHC's approximately $6.8 billion portfolio included 341 properties in 34 states and Washington, D.C., with more than 26,000 senior living units, approximately 7.4 million square feet of medical office and life science properties and occupied by approximately 450 tenants. DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with approximately $40 billion in assets under management as of June 30, 2025 and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, MA. For more information, visit A Maryland Real Estate Investment Trust with transferable shares of beneficial interest listed on the shareholder, Trustee or officer is personally liable for any act or obligation of the Trust. View source version on Contacts Bryan Maher, Senior Vice President(617) 796-8234 Sign in to access your portfolio

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Yahoo

time27 minutes ago

  • Yahoo

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2025, after the financial markets close on Tuesday, August 12, 1-877-704-4453 International: 1-201-389-0920 Conference ID: 13754684 Webcast: Webcast Link A live webcast of the conference call may also be found on the 'News & Events' page in the Investor Relations section of the Mineralys Therapeutics website. About Mineralys TherapeuticsMineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit Follow Mineralys on LinkedIn, Twitter and Bluesky. Contact: Investor Relations investorrelations@ Media RelationsMelyssa WeibleElixir Health Public RelationsPhone:1-201-723-5805Email: mweible@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store